

Tamoxifen with or without Ovarian Function Suppression as Adjuvant Hormonal Treatment in Premenopausal Breast Cancer Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree
In Clinical Oncology & Nuclear Medicine*

By

Eman El-Araby Mohamed
M.B, B.ch.

Supervised by

Prof. Khalid El Hussieny Nasr
*Professor of Clinical Oncology & Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Dr. Khaled Kamal El Ghoneimy
*Lecturer of Clinical Oncology & Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Dr. Ahmed Mohamed Gaballah
*Lecturer of Clinical Oncology & Nuclear Medicine
Faculty of Medicine - Ain Shams University*

Faculty of Medicine - Ain Shams University
2018

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قالوا

لسبحانك لا علم لنا
إلا ما علمتنا إنك أنت
العليم العظيم

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgment

*First and foremost, I feel always indebted to **ALLAH**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and
profound gratitude to **Prof. Khalid El Hussieny
Masr**, Professor of Clinical Oncology and Nuclear
Medicine, Faculty of Medicine-Ain Shams
University, for his keen guidance, kind supervision,
valuable advice and continuous encouragement,
which made possible the completion of this work.*

*I am deeply thankful to **Dr. Khaled Kamal
El Ghoneimy**, Lecturer of Clinical Oncology and
Nuclear Medicine, Faculty of Medicine-Ain Shams
University, for his great help, active participation
and guidance.*

*I am also delighted to express my deepest
gratitude and thanks to **Dr. Ahmed Mohamed
GabAllah**, Lecturer of Clinical Oncology and
Nuclear Medicine, Faculty of Medicine-Ain Shams
University, for his kind care, continuous
supervision, valuable instructions, constant help
and great assistance throughout this work.*

*I would like to express my hearty thanks to my
Husband and all my family for their support till
this work was completed.*

*Last but not least my sincere thanks and
appreciation to all patients participated in this study.*

Eman EL-Araby Mohamed

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	iv
Introduction	1
Aim of the Work	3
Review of Literature	
▪ Epidemiology and Risk Factors of Breast Cancer.....	4
▪ Clinical Features and Diagnosis.....	17
▪ Treatment Approach.....	45
▪ Tamoxifen	66
Patients and Methods.....	82
Results	85
Discussion.....	119
Summary and Conclusion.....	124
Recommendation.....	126
References	127
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Pharmacokinetic of tamoxifen MARTINDALE.	71
Table (2):	Summary of Studies	81
Table (3):	Total data collection.....	85
Table (4):	Follow up period (months).....	86
Table (5):	Age.....	86
Table (6):	Primary Breast Surgery.....	87
Table (7):	Primary TNM.	88
Table (8):	Hormone receptor status.	89
Table (9):	Adjuvant Chemotherapy.....	90
Table (10):	Adjuvant Radiotherapy.....	90
Table (11):	Toxicity analysis.....	91
Table (12):	Overall survival of all data.....	93
Table (13):	Overall survival of line treatment.....	94
Table (14):	Overall survival and its relation to the prognostic factors	95
Table (15):	OS with age group (≤ 35 years).	99
Table (16):	OS with age group (36-39 years)	100
Table (17):	OS with age group (≥ 40 years).	101
Table (18):	Disease free survival	106
Table (19):	DFS with line treatment.....	107
Table (20):	Disease free survival and its relation to the prognostic factors	108
Table (21):	DFS with age group (≤ 35 years).....	112
Table (22):	DFS with age group (36-39 years).....	113
Table (23):	DFS with age group (≥ 40 years)	114

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Mammogram showing a probable breast tumor.....	22
Figure (2):	Mammogram and MRI Breast Images Comparison	26
Figure (3):	Representative beam angles and plan for APBI with mini-tangents and electron field.....	47
Figure (4):	ER, oestrogen receptor; HER2, human epidermal growth factor 2receptor; ChT, chemotherapy; ET, endocrine therapy; T, trastuzumab	50
Figure (5):	Estrogen receptor and its domains.....	61
Figure (6):	Receptor binding with E2 and TAM.....	64
Figure (7):	Bold font denotes the enzyme(s) primarily involved in each step.....	67
Figure (8):	Adverse events of TAM.	92
Figure (9):	Overall survival of all data.	93
Figure (10):	Overall survival of line treatment.....	94
Figure (11):	Correlation of OS with different prognostic factors	96
Figure (12):	Overall survival with age group (≤ 35 years).....	99
Figure (13):	Overall survival with age group (36-39 years).....	100
Figure (14):	Overall survival (OS) in 3 year with age group (≥ 40 years).	101
Figure (15):	Overall survival of lymph node infiltration (N1) with line treatment	102
Figure (16):	Overall survival of Her-2neu with line treatment.....	104
Figure (17):	Overall survival of chemotherapy with line treatment	105
Figure (18):	Disease free survival.....	106

List of Figures (con.....)

Fig. No.	Title	Page No.
Figure (19):	Disease free survival with line treatment.....	107
Figure (20):	Disease free survival and its relation to the prognostic factors	109
Figure (21):	Disease free survival with age group (≤ 35 years).	112
Figure (22):	Disease free survival with age group (36-39 years)	113
Figure (23):	Disease free survival with age group (≥ 40 years)	114
Figure (24):	Disease free survival with tumor size (T1).....	115
Figure (25):	Disease free survival with tumor size (T2).....	116
Figure (26):	Disease free survival with tumor size (T3).....	117
Figure (27):	Disease free survival of Her-2 with line treatment.....	118

List of Abbreviations

Abb.	Full term
<i>ABCSG-12</i>	<i>The Austrian Breast and Colorectal Cancer Study Group phase III Trial</i>
<i>AIs</i>	<i>Aromatase inhibitors</i>
<i>ASCO</i>	<i>American Society of Clinical Oncology</i>
<i>BCDDP</i>	<i>Breast Cancer Detection Demonstration Project</i>
<i>BCRAT</i>	<i>Breast Cancer Risk Assessment Tool</i>
<i>BCS</i>	<i>Breast conservative surgery</i>
<i>BMD</i>	<i>Bone mineral density</i>
<i>BMI</i>	<i>Body mass index</i>
<i>BRCA</i>	<i>Breast cancer gene</i>
<i>CCNE1</i>	<i>Cyclin E1</i>
<i>CI</i>	<i>Confidence interval</i>
<i>CNB</i>	<i>Core needle biopsy</i>
<i>CR</i>	<i>Complete response</i>
<i>CT</i>	<i>Computed tomography</i>
<i>CTCAE</i>	<i>Common Terminology Criteria for Adverse Events</i>
<i>DCIS</i>	<i>Ductal carcinoma in situ</i>
<i>DFS</i>	<i>Disease free survival</i>
<i>DNA</i>	<i>Deoxy-nucleic acid</i>
<i>E-3193</i>	<i>Eastern Cooperative Oncology Group trial 3193</i>
<i>EBCTCG</i>	<i>Early Breast Cancer Trialists' Collaborative Group</i>
<i>ECOG</i>	<i>Eastern Cooperative Oncology Group</i>
<i>EDBC</i>	<i>Endocrine-dependent breast cancer</i>
<i>EGFR</i>	<i>Epidermal growth factor receptor</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>ER</i>	<i>Estrogen receptor</i>
<i>ERE</i>	<i>Estrogen response elements</i>
<i>ET</i>	<i>Endocrine therapy</i>
<i>FDA</i>	<i>U.S. Food and Drug Administration</i>
<i>FDG</i>	<i>Fluorodeoxyglucose</i>
<i>FGF</i>	<i>Fibroblast growth factor</i>
<i>FNA</i>	<i>Fine needle aspiration</i>
<i>FSH</i>	<i>Follicle-stimulating hormone</i>
<i>GGH</i>	<i>Gamma glutamyl hydrolase</i>
<i>GK</i>	<i>Gamma knife</i>
<i>GnRH</i>	<i>Gonadotropin-releasing hormone</i>
<i>HDL</i>	<i>High -density lipoprotein</i>
<i>HER</i>	<i>Human epidermal receptor</i>
<i>HER2</i>	<i>Human epidermal growth factor-2 receptor</i>
<i>HR</i>	<i>Hormonal receptor</i>
<i>LAPTMB4</i>	<i>Lysosome-associated transmembrane protein 4-beta</i>
<i>LBD</i>	<i>Ligand-binding domain</i>
<i>LCIS</i>	<i>Lobular carcinoma in situ</i>
<i>LDL</i>	<i>Low-density lipoprotein</i>
<i>LH</i>	<i>Luteinizing hormone</i>
<i>LHRH</i>	<i>Luteinizing hormone-releasing hormone</i>
<i>LVI</i>	<i>Lymphovascular invasion</i>
<i>M</i>	<i>Metastatic disease</i>
<i>MAPK</i>	<i>Mitogen activated protein kinases</i>
<i>MDR-1</i>	<i>Multidrug-resistant gene 1</i>
<i>MIBB</i>	<i>Minimally-invasive breast biopsy</i>
<i>N</i>	<i>Lymph node</i>
<i>NCCN</i>	<i>National Comprehensive Cancer Network</i>

List of Abbreviations (cont...)

Abb.	Full term
<i>NSABP</i>	<i>National Surgical Adjuvant Breast and Bowel Project</i>
<i>NSEP1</i>	<i>Nuclease sensitive element binding protein 1</i>
<i>OS</i>	<i>Overall survival</i>
<i>PFS</i>	<i>Progression free survival</i>
<i>PR</i>	<i>Progesterone receptor</i>
<i>ROLL</i>	<i>Radio guided occult lesion localization</i>
<i>RS</i>	<i>Recurrence score</i>
<i>RTK</i>	<i>ReceptorTyrosine Kinase</i>
<i>SDF- 1</i>	<i>Stromal cell-derived factor</i>
<i>SEER</i>	<i>Surveillance, Epidemiology, and End-Results</i>
<i>SERDs</i>	<i>Selective estrogen receptor down-regulators</i>
<i>SERMs</i>	<i>Selective oestrogen receptor modulators</i>
<i>SLNB</i>	<i>Sentinal lymph node</i>
<i>SOFT</i>	<i>Suppression of Ovarian Function Trial</i>
<i>SRC-1</i>	<i>Steroid receptor coactivator-1</i>
<i>T</i>	<i>Tumor size</i>
<i>TEXT</i>	<i>Tamoxifen and Exemestane Trial.</i>
<i>TNBC</i>	<i>Triple negative breast cancer.</i>
<i>VEGF</i>	<i>Amphiregulin and Vascular endothelial growth factor</i>
<i>WGL</i>	<i>Wire-guided localization</i>

INTRODUCTION

Breast cancer is the most frequently diagnosed cancer globally and is the leading cause of cancer-related death in women. The American Cancer Society estimates that 249,260 Americans will be diagnosed with invasive breast cancer and 40,890 will die of the disease in the United States in 2016 (*Siegel et al., 2016*).

The treatment of breast cancer includes the treatment of local disease with surgery, radiation therapy, or both, and systemic treatment with chemotherapy, endocrine therapy, biologic therapy, or combinations of these. The need for and selection of various local or systemic therapies are based on several prognostic and predictive factors. These factors include tumor histology, clinical and pathologic characteristics of the primary tumor, ALN status, tumor hormone receptor (ER/PR) content, tumor HER2 status (*NCCN Guidelines Version 2.2016*).

Adjuvant endocrine therapy is an integral component of care for endocrine-dependent breast cancer (EDBC). The goal of this type of therapy is to counteract the production and the action of estrogens (*Jankowitz et al., 2013*).

Adjuvant endocrine therapy with tamoxifen had been recommended for premenopausal women with hormone

receptor positive breast cancer during the past 15 years (*Howlader et al., 2013*).

The American Society of Clinical Oncology endorsed guidelines recommending that ovarian ablation or suppression not be added routinely to adjuvant therapy in premenopausal women (*Griggs et al., 2012*).

International consensus guidelines for breast cancer management in young women suggested that the addition of a gonadotropin-releasing hormone (GnRH) agonist to tamoxifen be discussed on an individualized basis (*Partridge et al., 2014*).

AIM OF THE WORK

This is a retrospective study aiming at evaluating the disease free survival, overall survival & toxicity profile in premenopausal breast cancer patient receiving *Tamoxifen* versus Tamoxifen with ovarian suppression (LHRH) agonists as adjuvant hormonal treatment

Chapter 1

EPIDEMIOLOGY AND RISK FACTORS OF BREAST CANCER

1- Epidemiology

In the United States, breast cancers remains the most frequent cancer in women and the second most frequent cause of cancer death. In 2017, it is estimated that approximately 252, 710 women will be diagnosed with invasive breast cancer, and 41, 610 women will die from the disease. Breast cancer death is expected to down by 34% as a result of improvements in early detection and treatment (*Jemal et al., 2017*).

Breast cancer is the most common cancer among women in Egypt. The proportion of breast cancer among Egyptian females was 32.0% followed by liver cancer 13.5%. The age standardized rate and the crude incidence rate for breast cancer per 100, 000 in lower Egypt (2009 to 2011) were 53 and 43.8, in middle Egypt (2009) were 35.6 and 25.8 and in upper Egypt (2008) were 64.5 and 45.3 respectively (*Amal et al., 2014*).

The total number of breast carcinomas in Ain Shams University was 2808 cases representing 99.5% of all malignant breast tumors and 23.9% of the total malignancies (*Thanana et al., 2015*).

Breast cancer is the most common cancer among females (2002-2010), accounting 37.5% in National Cancer Institute and 19.6% in both genders (*Nelly et al., 2014*)

In the early 1980s, breast cancer rates rose steeply by 3.7 percent per year over the baseline incidence. After increasing from 1994 to 1999, breast cancer incidence rates remained stable from 2000 to 2009. The increase in breast cancer incidence through the 1990s was seen mostly in early stage and in situ cancers, and was attributed to increased detection of early stage disease because of screening. However, environmental factors and increased lifetime estrogen exposure likely also contributed to the higher incidence (*Jemal et al., 2013*).

2- Risk factors

Multiple factors were associated with an increased risk of developing breast cancer, but the majority of these factors convey a small to moderate increase in risk for any individual woman (*Jemal et al., 2009*).

▪ Age:

It has been estimated that approximately 50% of women who develop breast cancer have no identifiable risk factor beyond increasing age and female gender. The importance of age as a breast cancer risk factor is sometimes overlooked. In 2009, it was estimated that 18, 640 invasive breast cancers and